Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …

Abstract Lutetium-177 [T½= 6.76 d; E β (max)= 0.497 MeV; maximum tissue range~ 2.5 mm;
208 keV γ-ray] is one of the most important theranostic radioisotope used for the …

Bone metastases are a painful and complex condition that overwhelmingly impacts the
prognosis and quality of life of cancer patients. Over the years, nuclear medicine has made …

In this study, we explore the interactions of photons, protons, and alpha with matter in the
context of two drugs, MDPLu and EDTMPLu, delving into the interesting field of radiation …

Radionuclide‑based therapy represents a novel treatment regimen for tumors. Among these
therapies, lutetium‑177 (177 Lu) has gained significant attention due to its stability and …

Prostate cancer (PCa) is one of the preeminent causes of mortality in men worldwide.
Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose …

Radiopharmaceutical approaches for targeting bone metastasis have traditionally focused
on palliation of pain. Several agents have been clinically used over the last several decades …

Clinical Nuclear Medicine Log in or Register Get new issue alertsGet alerts Subscribe to
journal Secondary Logo Journal Logo Advanced Search Toggle navigation Register Login …

The cell is the basic unit of life in all forms of living organisms, from the smallest bacterium to
the most complex animal. On the basis of microscopic and biochemical differences, living …

Breast Cancer (BC) is the leading cause of cancer-related deaths in women and the most
common cancer worldwide. It is classified based on its anatomical origin, the presence of …